Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial

Written By Yiran Gan
Target Engagement and Immunogenicity of an Active Immunotherapeutic Targeting Pathological α-Synuclein: A Phase 1 Placebo-Controlled Trial - Eijsvogel et al. 2024

Target Engagement and Immunogenicity of an Active Immunotherapeutic Targeting Pathological α-Synuclein: A Phase 1 Placebo-Controlled Trial

Publication Date: 2024.06.20

Authors: Pepijn Eijsvogel, Pinaki Misra, Luis Concha-Marambio, Justin D. Boyd, Shuang Ding, Lauren Fedor, Yueh-Ting Hsieh, Yu Shuang Sun, Madeline M. Vroom, Carly M. Farris, Yihua Ma, Marieke L. de Kam, Igor Radanovic, Maurits F. J. M. Vissers, Dario Mirski, Ghazal Shareghi, Mohammad Shahnawaz, Wolfgang Singer, Philip Kremer, Geert Jan Groeneveld, Hui Jing Yu & Jean-Cosme Dodart

Journal: Nature Medicine volume 30, pages 2631–2640 (2024)

Citation

Pepijn Eijsvogel, Pinaki Misra, Luis Concha-Marambio, Justin D. Boyd, Shuang Ding, Lauren Fedor, Yueh-Ting Hsieh, Yu Shuang Sun, Madeline M. Vroom, Carly M. Farris, Yihua Ma, Marieke L. de Kam, Igor Radanovic, Maurits F. J. M. Vissers, Dario Mirski, Ghazal Shareghi, Mohammad Shahnawaz, Wolfgang Singer, Philip Kremer, Geert Jan Groeneveld, Hui Jing Yu & Jean-Cosme Dodart
Nature Medicine volume 30, pages 2631–2640 (2024)

Article Link

https://www.nature.com/articles/s41591-024-03101-8

© 2024 Eijsvogel, Misra, Concha-Marambio, Boyd, and colleagues

Nature Medicine - Springer Nature

Hello, World!

Yiran Gan
Previous

White matter alterations and their associations with biomarkers and behavior in subjective cognitive decline individuals: a fixel-based analysis
Next

The Ratio of Plasma Amyloid-β 1-42 over Serum Albumin Can Be a Novel Biomarker Signature for Diagnosing End-Stage Renal Disease-Associated Cognitive Impairment